NanoLogix Technology Delivers Live Tuberculosis (TB) Detection Results in a Revolutionary 4 Days versus Traditional 21 Days
November 01 2011 - 9:31AM
Business Wire
NanoLogix (Pink Sheets: NNLX), an innovator in the rapid
detection, identification and antibiotic sensitivity determination
of live bacteria announced today third-party results for detecting
live Mycobacterium tuberculosis (TB) in a revolutionary time of 4
days with its BNP (BioNanoPore) technology. The advanced culture
test results with the NanoLogix BNP technology are at least 500%
faster than the 21-day standard for live TB culture detection.
Additionally, other test methods for tuberculosis are expensive,
labor intensive and cannot determine if a microbe found in a sample
is living or dead. The NanoLogix technology provides a significant
advantage over conventional methods for detecting TB in developing
regions where medical resources are scarce and TB infections are
rampant.
The 4-day TB results are a part of a lab research study
conducted by a well-respected third party laboratory. The
organization maintains anonymity until research data is published
in a leading scientific journal.
"We are ecstatic over the third-party 4-day TB test results,"
said Bret Barnhizer, CEO of NanoLogix. "Typically, physicians must
wait at least 21 days to determine if a patient should be put on
antibiotics for TB. With an annual death toll of well over one
million from this devastating disease, providing definitive, viable
determination of TB in 4 days is a true game-changer."
The World Health Organization estimates that roughly one third
of the world's population is infected with TB, either in an active
or latent form. Highly contagious, active tuberculosis infections
commonly attack the lungs and have a 50% mortality rate. In recent
decades, the misdiagnosis and mismanagement of TB infections have
led to a number of antibiotic-resistant strains, such as Mutli-Drug
Resistant Tuberculosis and Extensively Drug Resistant TB.
Because of its slow growing nature, speeding up the definitive
diagnosis of live-cell TB detection has been a consistent challenge
for the medical industry. While techniques such as X-ray
examinations, smear tests and DNA sequencing have provided
alternatives to 21 day culture results, their inability to
differentiate between the simple presence of a bacteria and a true
active infection have left them unable to provide a comprehensive
tool for fighting TB.
"By making the 'gold standard' method of culturing a faster
process, our technology has the potential of providing the medical
community with an extremely rapid, accurate, affordable and
definitive culture-based TB test," continued Barnhizer. "With
NanoLogix, physicians will soon have the opportunity to detect live
TB faster, administer antibiotics properly, and monitor the
efficacy of antibiotics in a close to real-time mode. This will
provide the opportunity to reduce the prevalence of TB infections
around the world."
NanoLogix Technology Granted Chinese Patent
In a milestone for the company, NanoLogix is pleased to announce
it has been granted a foundational patent by China for its BNC
(BioNanoChannel) detection technology. In addition to patents
pending with the USPTO, the company has multiple patent
applications pending in China, India, Brazil, Japan, Russia and
Europe for their BNC, BNP and BNF (BioNanoFilter) detection
technologies.
NanoLogix Featured on the Cover of Medical Design
Magazine
NanoLogix is pleased to announce it is featured on the current
cover of Medical Design magazine. The prestigious health care
industry magazine enjoys a circulation of over 34,000 and a pass
along circulation of around 200,000. The feature article on
NanoLogix provides a detailed overview of its technology, benefits
and third party validations. The full PDF of the article can be
found at
www.nanologix.com/cms-assets/documents/36868-882819.20111001-medical-desig-2.pdf.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid
diagnostics. Its products offer accelerated detection and
identification of microorganisms. In addition to medical and
homeland security applications, NanoLogix technology is applicable
in pharmaceutical, industrial, veterinary and environmental
testing. Patents granted to NanoLogix can be used in the areas of
applied microbiology, soil microbiology and bioremediation,
microbial physiology, molecular biology, pharmacology,
pharmaco-kinetics, and antibiotic sensitivity. For more information
visit www.nanologix.com.
This press release contains statements, which may constitute
"forward- looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of NanoLogix, Inc., and members of its
management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results.
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Apr 2024 to May 2024
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From May 2023 to May 2024